SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: coyote who wrote (1020)5/17/1998 1:05:00 AM
From: George Holt  Read Replies (1) of 2135
 
Cancer Drug May Be Tested This Year

.c The Associated Press

)

CHICAGO (AP) - The researcher who discovered two drugs that have eliminated cancer tumors in mice said he has received federal permission to treat about 30 terminally ill patients who have not responded to other drugs.

The first, very limited tests of the drugs on humans could come by the end of the year or early next year, Dr. Judah Folkman told the Chicago Tribune in a story for Sunday editions.

The drugs, angiostatin and endostatin, are highly experimental and have been tried only in mice, where they have caused cancerous tumors to permanently disappear.

Folkman told the Tribune in an interview Friday that angiostatin and endostatin are being produced by a National Cancer Institute facility, not in mass quantities, ''but just enough for a small number of patients.''

''So far, they're right on schedule for December or the first of the year. That's our hope,'' he said.

Folkman said he has received permission to treat the patients on a ''compassionate basis,'' a protocol reserved for desperately ill patients under which federal requirements for pre-clinical testing are waived.

It will still be 12 to 18 months before the company licensed to develop the drugs will have enough to begin full-scale clinical human trials.

AP-NY-05-17-98 0056EDT

George

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News